The July issue of The American Journal of Gastroenterology highlights new clinical science including using a smartphone app to assess stool form, rural-urban disparities in cirrhosis mortality, and lung infection risk in severe alcohol-related hepatitis. This issue also includes articles on pediatric IBD, therapy options for Crohn’s disease, a novel endoscopic suturing device, proton pump inhibitors, and more.
November Issue of The American Journal of Gastroenterology Discusses Association Between BMI and Early-Onset Colorectal Cancer Risk, PPIs and All-Cause Mortality
The November issue of The American Journal of Gastroenterology features several articles examining the association between common conditions or treatments and the risk for disease development, including a study on the association between higher body mass index and increased risk for early-onset colorectal cancer, and a population study on proton pump inhibitors and all-cause mortality.
August Issue of Issue of The American Journal of Gastroenterology Includes Diet-Associated NAFLD Risk and Increased Risk of Mortality from COVID-19 Among PPI Users
The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.
Study on Green Kiwifruit to Treat Chronic Constipation and New ACG Clinical Guidelines on C. difficile Infection Featured in the June Issue of The American Journal of Gastroenterology
The June issue of AJG includes articles on the effectiveness of OTC therapies and green kiwifruit as a dietary therapy for chronic constipation, as well as new ACG Guidelines on the Prevention, Diagnosis, and Treatment of C. difficile infections, and more.
Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors (PPIs)
Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.